| Literature DB >> 27297283 |
J M Hillger1, C Diehl1, E van Spronsen1, D I Boomsma2, P E Slagboom3, L H Heitman1, A P IJzerman4.
Abstract
Genetic differences between individuals that affect drug action form a challenge in drug therapy. Many drugs target G protein-coupled receptors (GPCRs), and a number of receptor variants have been noted to impact drug efficacy. This, however, has never been addressed in a systematic way, and, hence, we studied real-life genetic variation of receptor function in personalized cell lines. As a showcase we studied adenosine A2A receptor (A2AR) signaling in lymphoblastoid cell lines (LCLs) derived from a family of four from the Netherlands Twin Register (NTR), using a non-invasive label-free cellular assay. The potency of a partial agonist differed significantly for one individual. Genotype comparison revealed differences in two intron SNPs including rs2236624, which has been associated with caffeine-induced sleep disorders. While further validation is needed to confirm genotype-specific effects, this set-up clearly demonstrated that LCLs are a suitable model system to study genetic influences on A2AR response in particular and GPCR responses in general.Entities:
Keywords: Adenosine (PubChem CID: 60961); Adenosine A(2A) receptor; BAY60-6583 (PubChem CID: 11717831); CCPA (PubChem CID: 123807); CGS21680 (PubChem CID: 3086599); Cl-IB-MECA (PubChem CID: 3035850); G protein-coupled receptors; Istradefylline (PubChem CID: 5311037); LUF5448 (PubChem CID: 69538223); Label-free; Lymphoblastoid cell lines; NECA (PubChem CID: 448222); Precision medicine; Single Nucleotide Polymorphism; ZM241385 (PubChem CID: 176407)
Mesh:
Substances:
Year: 2016 PMID: 27297283 DOI: 10.1016/j.bcp.2016.06.006
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858